#United States #Minneapolis #Francis Medical #Vanquish #VAPOR 2

Francis Medical Achieves Milestone in Prostate Cancer Research

On February 25, 2025, Francis Medical, Inc., a pioneering medical device firm, proudly announced it has successfully completed patient enrollment for the VAPOR 2 pivotal clinical study. This clinical trial seeks to explore an innovative water vapor ablation therapy, aimed at treating prostate cancer—a condition impacting a staggering 1 in 8 men in the U.S. at some point in their lifetimes.

The VAPOR 2 Study

The VAPOR 2 study includes a significant participant group, with 235 men diagnosed with intermediate-risk, localized prostate cancer being treated at 26 clinical sites across the U.S. This multicenter, single-arm study will gather essential data to support the 510(k) clearance process of Francis Medical's Vanquish device, projected to begin in July 2025. Following the study, participants will be monitored for five years to assess the long-term outcomes of this groundbreaking therapy.

Dr. Samir Taneja, an expert from NYU Langone, and Dr. Arvin George from Johns Hopkins University are leading the research as co-principal investigators. Dr. Taneja expressed excitement about the study’s early completion, stating, "For a study of this scale to finish enrollment early is a remarkable achievement. It highlights the dedication of our research team and the excitement surrounding this innovative therapy."

The Need for Advanced Treatments

Prostate cancer remains the second most prevalent cancer among men in the United States. Traditional treatment approaches often lead to serious side effects, including urinary incontinence and erectile dysfunction. These complications can severely affect a patient’s quality of life, driving the need for more effective and gentle treatment options.

Francis Medical's Vanquish device employs advanced thermal water vapor technology, which utilizes sterile water vapor to selectively destroy cancer cells. This innovative approach aims to minimize damage to adjacent tissues by respecting the prostate's natural anatomy, promising a potentially safer experience for patients.

Michael Kujak, the president and CEO of Francis Medical, acknowledged the teamwork that led to this success: "This achievement stems from the seamless collaboration of our dedicated team, researchers, and, most importantly, the patients involved. We thank the VAPOR 2 participants for their invaluable contribution to advancing prostate cancer treatment."

A Vision for Patient-Centric Care

Michael Hoey, the founder and chief technology officer at Francis Medical, reiterated the company's commitment to enhancing patient experiences. He reflected on the transformative potential of their technology, saying, "Seeing our years of work lead to an improvement in the quality of life for men confronting prostate cancer is incredibly rewarding."

Francis Medical's mission has been inspired by the personal journey of Hoey's father, who faced debilitating prostate cancer treatments that markedly impacted his life. Established to change the narrative surrounding prostate cancer treatment, the company's water vapor technology aims to provide a gentler, more effective approach. As advancements in urological cancer treatment continue, Francis Medical is dedicated to fulfilling its promise of being tough on cancer while being gentle on patients.

To learn more about the revolutionary therapy being studied, or to follow the VAPOR 2 study's progress, please visit Francis Medical's official site. The Vanquish Water Vapor Ablation System is currently classified as an investigational device specifically for prostate cancer treatment.

In closing, the completion of enrollment for the VAPOR 2 study marks a significant step towards innovating prostate cancer treatment—a goal driven by compassion, scientific advancement, and a focus on patient well-being. As the research unfolds, the hope is that Vanquish will redefine cancer care for countless men facing formidable challenges.